Advice
following a full submission
sacubitril/valsartan (Entresto®) is accepted for use within NHS Scotland.
Indication under review: in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.
Sacubitril/valsartan, compared to an angiotensin-converting enzyme inhibitor, significantly reduced rates of the composite outcome of cardiovascular death and hospitalisation for heart failure, rates of the component outcomes and of all cause mortality.
Download detailed advice215KB (PDF)
Medicine details
- Medicine name:
- sacubitril/valsartan (Entresto)
- SMC ID:
- 1132/16
- Indication:
- In adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 March 2016